Chairman and Chief Executive Officer
Mr. Michael Frank is the Chairman of the Board and CEO of Revive. Mr. Frank has a strong background in operations, business development, M&A and the capital markets. Mr. Frank is currently the President of Mifran Consulting, providing advisory services to emerging technology companies in a number of key verticals. In the past, Mr. Frank has served as the CEO and Director of Sprylogics International and the Internet of Things Inc., as well as holding senior management positions at Ernst & Young, Data General, and NCR. Mr. Frank has had successful exits in the technology sector including one to Intuit Corporation, and has been instrumental in advising several early stage software companies including a number in the cannabis sector over the last few years. Additionally, Mr. Frank has consulted to Revive’s senior management team on various strategic initiatives.
ChIEF FINANCIAL Officer
Mr. Marrelli holds a Bachelor of Commerce degree from the University of Toronto and is qualified as a Chartered Accountant and as a Certified General Accountant in Canada. Mr. Marrelli has been a principal of Marrelli Support Services Inc., a firm providing administration services to Canadian public companies, since February 2009 and, prior to February 2009, a partner with Marrelli & Drake Corporate Services (formerly Duguay & Ringler Corporate Services) (a firm providing administration services to Canadian public companies). Mr. Marrelli also serves as the Chief Financial Officer of several publicly-listed junior mining companies and as a director of Odyssey Resources Limited, an Exchange listed issuer.
Derrick Welsh brings 14 years of Health Care experience, with the past 5 years in the Cannabis industry. Derrick has worked with several high profile publicly traded Cannabis companies like Xanthic Bio Pharma and Green Growth Brands. During this time, he developed several patent pending formulations. The formulations he developed are for water Soluble THC and CBD products such as beverages, water enhancers and effervescent tablets. He has developed quality systems, standard operating procedures and method validation for production of these products. Leveraging his previous experience with cannabinoids Derrick found opportunity in the upcoming psychedelics marketspace. Derrick developed a catalog of formulations, extraction and purification technology for the compound Psilocybin. The 6 products that Psilocin Pharma Corp created come with different dosages and can titrated to suit clinical trials or public consumption in markets where Psilocybin is legal. With the FDA Granting “Break Through Status” for Psilocybin in treatment of depression & anxiety, Derrick believes this as an opportunity to provide adjunct alternatives to patients to whom have had minimal success with traditional medication.